DOSIsoft PLANET® Onco Dose receives CE MDR Mark and new FDA 510(k) clearance

This advanced software version allows clinics to cover a broader range of therapies by supporting voxel-based dose computation for 90Y, ¹⁷⁷Lu ¹⁶⁶Ho and ¹³¹I isotopes with the flexibility to incorporate new beta/gamma emitters. This advanced software version allows clinics to cover a broader range of therapies by supporting voxel-based dose computation for 90 Y, ¹⁷⁷Lu ¹⁶⁶Hoand¹³¹Iisotopes with the flexibility to incorporate new beta/gamma emitters. Clinicians can benefit from...

PARIS, 07/04/2025 (informazione.news - comunicati stampa - salute e benessere)

This advanced software version allows clinics to cover a broader range of therapies by supporting voxel-based dose computation for and isotopes with the flexibility to incorporate new beta/gamma emitters.

Clinicians can benefit from optimized and newly introduced – reducing workload, enhancing patient comfort, streamlining clinical processes while ensuring accuracy. Validated against thorough Monte-Carlo simulations, it offers clinical-ready GPU-accelerated performances.

"All-in-one dosimetry solution for Patient specific Theranostics," PLANET enables highly personalized treatments including , , , , and more.

PLANET Onco Dose is CE Marked under new EU MDR Regulation 2017/745 since February 17 , 2025. Learn more.

PLANET Onco Dose is US FDA 510(k) cleared since March 14 , 2025, expanding previous market clearance to version 3.2 rich feature set. As per FDA general rule for Radiopharmaceutical Therapy (RPT), voxel-based dosimetry solutions are intended specifically for absorbed dose calculation and should only be used with approved radioactive products. Learn more.

highlights Marc Uszynski , CEO at DOSIsoft. 

Founded in 2002, DOSIsoft stands as market leader specialized in dosimetry software in Radiation Oncology and Nuclear Medicine to improve cancer patient safety and treatment quality. DOSIsoft provides the most competitive patient-specific quality assurance and medical imaging solutions in over 600 hospital centers in 60 countries. Spin-off between Gustave Roussy and Curie Institute in France , DOSIsoft constantly innovates in partnership with leading cancer institutes and research centers in the world, like recently through the Thera4Care European project. www.dosisoft.com.

Logo: https://mma.prnewswire.com/media/2657593/DOSIsoft_Logo.jpg

Mme Xiaolu Chen
Service Marketing
xiaolu.chen@dosisoft.com 

View original content:https://www.prnewswire.co.uk/news-releases/dosisoft-planet-onco-dose-receives-ce-mdr-mark-and-new-fda-510k-clearance-302420678.html